Loading...
•
Dec 31, 2025
AbCellera Q4 2025 Earnings Report
AbCellera Q4 2025 Earnings Report
Key Takeaways
AbCellera reported a strong fourth quarter in 2025, driven by a significant patent litigation settlement that accounted for 60% of the year's total revenue. The company successfully transitioned into a clinical-stage biotech with two internal programs in trials and maintained a robust liquidity position of approximately $700 million.
Transitioned to a clinical-stage company with ABCL635 entering Phase 2 and ABCL575 in Phase 1.
Q4 revenue of $44.9 million was primarily driven by an upfront patent litigation settlement.
Maintained a strong balance sheet with $561 million in cash and marketable securities, plus $135 million in government funding.
Cumulative molecules in the clinic increased to 19, up from 16 at the end of 2024.
Revenue by Segment
Forward Guidance
AbCellera expects its current liquidity to fund operations and pipeline investments for well beyond the next three years.
Positive Outlook
- Sufficient liquidity to fund operations for over three years.
- Fully built platform and clinical manufacturing facility now operational.
- Growing pipeline with multiple potential first-in-class programs.
- Important near-term clinical readouts expected.
- Access to $135 million in remaining non-dilutive government funding.
Challenges Ahead
- Company remains in a net loss position.
- R&D expenses are increasing as more programs move to clinical stages.
- Revenue is currently highly dependent on non-recurring items like litigation settlements.
- Ongoing heavy investment required for internal program development.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...